EMMANUEL AHIPUE: Open Payments
NPI 1104235092 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$760 in 29 payments from 7 companies in 2025. Trend: 2023 $861 · 2024 $676 · 2025 $760
Food & beverage: $640Education: $119
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $172 |
| E.R. Squibb & Sons, L.L.C. | 5 | $135 |
| Neurocrine BioSciences, Inc. | 5 | $108 |
| Otsuka America Pharmaceutical, Inc. | 4 | $102 |
| Lundbeck LLC | 4 | $98 |
| Alkermes, Inc. | 3 | $77 |
| Gilead Sciences, Inc. | 3 | $68 |
Products named: COBENFY, INGREZZA, REXULTI, ARISTADA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, AUSTEDO XR, VIVITROL.
Industry payments across NY — which companies pay providers there.
